EP 4400495 A1 20240717 - DOPAMINE D3/D2 RECEPTOR MODULATING COMPOUNDS
Title (en)
DOPAMINE D3/D2 RECEPTOR MODULATING COMPOUNDS
Title (de)
DOPAMIN-D3/D2-REZEPTOR-MODULIERENDE VERBINDUNGEN
Title (fr)
COMPOSÉS MODULANT LE RÉCEPTEUR D3/D2 DE LA DOPAMINE
Publication
Application
Priority
US 202363479530 P 20230111
Abstract (en)
The present disclosure provides for compounds of Formula (I):wherein R<sup>1</sup> has any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions including schizophrenia. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
IPC 8 full level
C07D 295/155 (2006.01); A61P 25/18 (2006.01)
CPC (source: EP KR)
A61K 31/495 (2013.01 - KR); A61P 25/18 (2018.01 - EP KR); C07D 295/135 (2013.01 - KR); C07D 295/155 (2013.01 - EP)
Citation (applicant)
- WO 2010070370 A1 20100624 - RICHTER GEDEON NYRT [HU], et al
- WO 2005012266 A1 20050210 - RICHTER GEDEON VEGYESZET [HU], et al
- SOKOLOFF, P. ET AL., NATURE, vol. 347, 1990, pages 146
- SCHWARTZ, J.-C. ET AL., CLIN. NEUROPHARMACOLOGY., vol. 16, 1993, pages 295
- "GenBank", Database accession no. U32499
Citation (search report)
- [Y] WO 2005012266 A1 20050210 - RICHTER GEDEON VEGYESZET [HU], et al
- [Y] EP 4056568 A1 20220914 - SHANGHAI HANSOH BIOMEDICAL CO LTD [CN], et al
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
EP 4400495 A1 20240717; JP 2024098972 A 20240724; KR 20240112213 A 20240718; WO 2024150068 A2 20240718; WO 2024150068 A3 20240822
DOCDB simple family (application)
EP 24151077 A 20240110; IB 2024000026 W 20240110; JP 2024001696 A 20240110; KR 20240002897 A 20240108